Latest Insider Transactions at Kinnate Biopharma Inc. (KNTE)
This section provides a real-time view of insider transactions for Kinnate Biopharma Inc. (KNTE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kinnate Biopharma Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kinnate Biopharma Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 14
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
30,700
+0.44%
|
$276,300
$9.94 P/Share
|
|
Feb 11
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
156,000
+4.3%
|
$1,560,000
$10.22 P/Share
|
|
Feb 11
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
156,000
+4.3%
|
$1,560,000
$10.22 P/Share
|
|
Dec 07
2020
|
James B. Tananbaum |
BUY
Conversion of derivative security
|
Indirect |
9,838,311
+40.47%
|
-
|
|
Dec 07
2020
|
Carl L Gordon Director |
BUY
Conversion of derivative security
|
Indirect |
3,097,929
+27.66%
|
-
|
|
Dec 07
2020
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
3,097,929
+27.66%
|
-
|
|
Dec 07
2020
|
Foresite Capital Management Iv, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
9,838,311
+40.47%
|
-
|
|
Dec 03
2020
|
James B. Tananbaum |
BUY
Open market or private purchase
|
Indirect |
1,000,000
+50.0%
|
$20,000,000
$20.0 P/Share
|
|
Dec 03
2020
|
Foresite Capital Management Iv, LLC > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
1,000,000
+50.0%
|
$20,000,000
$20.0 P/Share
|
|
Dec 02
2020
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
750,000
+50.0%
|
$15,000,000
$20.0 P/Share
|
|
Dec 02
2020
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
750,000
+50.0%
|
$15,000,000
$20.0 P/Share
|